Clarus Therapeutics (NASDAQ:CRXT) Coverage Initiated by Analysts at Truist Financial

Truist Financial began coverage on shares of Clarus Therapeutics (NASDAQ:CRXT) in a research report sent to investors on Wednesday morning, TipRanks reports. The firm issued a buy rating and a $10.00 target price on the stock.

Several other research firms also recently weighed in on CRXT. Truist started coverage on Clarus Therapeutics in a research note on Wednesday. They issued a buy rating and a $10.00 price target on the stock. Truist Securities started coverage on Clarus Therapeutics in a research note on Wednesday. They issued a buy rating and a $10.00 price target on the stock. Needham & Company LLC started coverage on Clarus Therapeutics in a research note on Wednesday, October 6th. They issued a buy rating and a $12.00 price target on the stock. Oppenheimer started coverage on Clarus Therapeutics in a research note on Monday, September 20th. They issued an outperform rating and a $12.00 price target on the stock. Finally, Cantor Fitzgerald started coverage on Clarus Therapeutics in a research note on Monday, September 20th. They issued an overweight rating and a $20.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Clarus Therapeutics presently has a consensus rating of Buy and an average price target of $12.43.

CRXT stock opened at $5.29 on Wednesday. Clarus Therapeutics has a fifty-two week low of $3.43 and a fifty-two week high of $31.24.

Clarus Therapeutics Company Profile

Clarus Therapeutics Inc is a specialty pharmaceutical company which provide solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women. The Company’s commercial product includes JATENZO(R). Clarus Therapeutics Inc, formerly known as Blue Water Acquisition Corp., is based in NORTHBROOK, Ill.

Featured Story: Stock Symbols Definition, Examples, Lookup

Analyst Recommendations for Clarus Therapeutics (NASDAQ:CRXT)

Receive News & Ratings for Clarus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.